Syngene International Limited is a leading contract research organization (CRO) based in Bangalore, India. Established in 1993 as a subsidiary of Biocon Limited, Syngene has grown to become one of the largest and most trusted CROs in the Asia-Pacific region. The company offers a wide range of integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, and agrochemical companies worldwide.
With state-of-the-art research facilities spanning over 1.8 million square feet, Syngene is equipped with cutting-edge technologies and a highly skilled workforce of over 5,000 scientists, researchers, and support staff. The company's multidisciplinary expertise covers various domains, including medicinal chemistry, biology, toxicology, formulation development, and analytical research.
Syngene's discovery services encompass early-stage drug discovery, target identification and validation, hit-to-lead optimization, and lead optimization. The company's experienced scientists collaborate closely with clients to design and execute customized research programs, leveraging their extensive knowledge and access to advanced technologies. Syngene's discovery capabilities have contributed to the successful development of several novel drug candidates across therapeutic areas such as oncology, immunology, metabolic disorders, and infectious diseases.
In addition to discovery services, Syngene offers a comprehensive range of development services, including preclinical development, clinical development, and regulatory support. The company's preclinical development services cover safety assessment, pharmacokinetics, and toxicology studies, enabling clients to make informed decisions about the safety and efficacy of their drug candidates. Syngene's clinical development services include clinical trial management, data management, biostatistics, and medical writing, ensuring efficient and compliant execution of clinical trials.
Syngene's manufacturing services encompass small molecule active pharmaceutical ingredient (API) manufacturing, formulation development, and analytical development. The company's state-of-the-art manufacturing facilities comply with global regulatory standards, enabling the production of high-quality APIs and formulations for clinical trials and commercial supply. Syngene's analytical development capabilities support the characterization, stability testing, and quality control of drug substances and drug products.
As a trusted partner to the global life sciences industry, Syngene has established long-term collaborations with numerous multinational companies. The company's client base includes several top-tier pharmaceutical companies, biotechnology startups, and academic institutions. Syngene's commitment to quality, confidentiality, and timely delivery has earned it a reputation for excellence and reliability in the industry.
Syngene's dedication to innovation is reflected in its continuous investment in research and development. The company has a strong focus on building internal capabilities and expanding its scientific expertise. Syngene's collaborations with academic institutions and research organizations further enhance its research capabilities and enable access to the latest scientific advancements.
In conclusion, Syngene International Limited is a leading contract research organization that offers a comprehensive range of integrated discovery, development, and manufacturing services to the global life sciences industry. With its state-of-the-art facilities, multidisciplinary expertise, and commitment to innovation, Syngene continues to play a crucial role in accelerating the development of novel therapeutics and contributing to the advancement of healthcare worldwide.
